The systemic administration of the anti-CEA immunotoxin, called MFE23GRNLY, has shown directionality against tumors positive for CEA expression and cytotoxic capacity superior to GRNLY in a murine model [21] constituting the proof of concept of this new anti-tumor treatment. The gene discussed is CEACAM5; the disease is neoplasm.